Login
Divisions and Subsidiaries
Forest Pharmaceuticals
Forest Laboratories Europe
Cerexa, Inc.
Forest Laboratories Canada Inc.
About Forest
Overview
Forest identifies, develops, and delivers therapies that make a meaningful difference in people's lives
Products
Research
News
Investor Center
Overview
Forest is building on a strong track record of commercial achievement to deliver important new medicines and strengthen our therapeutic franchises
Annual Reports
Stock Information
Webcasts &
Presentations
Partnerships
Overview
Forest partners with biotech and pharmaceutical companies to develop and bring promising new medicines to market
Capabilities
Careers
Overview
Joining Forest is an opportunity to become part of a forward-thinking community dedicated to helping improve patients' lives through medicine
Job Search
About Forest
Products
Research
News
Media Resources
Press Release Archive
All Press Releases
Business Development News
Corporate News
Financial News
Product News
R&D News
Product News
03.30.2005
Forest Laboratories, Inc. Receives Non-Approvable Letter for Social Anxiety Disorder Indication for Lexapro(R)
03.21.2005
New COMBUNOX(TM) (Oxycodone HCl and Ibuprofen) Tablets (CII) Now Available for the Short-Term Treatment of Acute, Moderate to Severe Pain
03.01.2005
Forest Laboratories, Inc. Receives Non-Approvable Letter for Panic Disorder Indication for Lexapro(R)
02.09.2005
Forest Laboratories Starts Confirmatory Study of Desmoteplase A Novel Investigational Treatment For Acute, Ischemic Stroke
01.11.2005
First New Treatment for Alcoholism in Ten Years, Now Available Campral(R) (Acamprosate Calcium) Delayed-Release Tablets
11.26.2004
FDA Approves Combunox(TM) (Oxycodone HCl and Ibuprofen) Tablets (CII) for the Short-Term Treatment Of Acute, Moderate to Severe Pain
09.23.2004
Glenmark Pharmaceuticals and Forest Laboratories Announce Collaboration Agreement on PDE4 Inhibitor for Asthma and COPD
08.31.2004
Forest Announces That Neramexane Did Not Demonstrate Statistical Significance in Recently Completed Phase III Trial in Patients with Moderate to Severe Alzheimer's Disease
08.26.2004
Forest Laboratories Submits Response for Lexapro(R) for Panic Disorder
07.29.2004
FDA Approves Campral(R) (Acamprosate Calcium) Delayed-Release Tablets for the Treatment of Alcohol Dependence
« first
‹ previous
…
5
6
7
8
9
10
11
12
13
next ›
last »